3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
80
Stomach Neoplasms
66
Rectal Neoplasms
39
Pancreatic Neoplasms
31
Colonic Neoplasms
27
Esophageal Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
20
Neoplasms
19
Adenocarcinoma
19
Cholangiocarcinoma
16
Neoplasm Metastasis
15
Adenocarcinoma Of Esophagus
14
Biliary Tract Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Ovarian Neoplasms
10
Gastrointestinal Neoplasms
7
Gallbladder Neoplasms
7
Carcinoma, Hepatocellular
7
Locally Advanced Rectal Cancer
6
Esophageal Squamous Cell Carcinoma
6
Endometrial Neoplasms
6
Recurrence
4
Lymphoma
4
Carcinoma
4
Bile Duct Neoplasms
4
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Peritoneal Neoplasms
3
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Oxaliplatin
×
1 year
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled